Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022
Journal of Antimicrobial Chemotherapy · 01.10.2024 · 79 (10) · 2575-2585
DOI: 10.1093/jac/dkae260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 24.07.2024. Verfasst von Zhaoquan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Guangxi University of Chinese Medicine, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
To investigate the epidemic patterns of pretreatment drug resistance (PDR) and acquired drug resistance (ADR) in HIV-1 sequences from China.
Methods
HIV-1 pol sequences and associated epidemiological data were collected from the Los Alamos HIV Sequence Database, NCBI, HIV Gene Sequence Database and PubMed. Genotypic resistance and subtypes were identified using the Stanford HIV Drug Resistance Database.
Results
A total of 36 263 sequences from ART-naïve individuals and 1548 sequences from ART-experienced individuals with virological failure were evaluated. PDR prevalence was 6.64%, initially decreasing and then increasing to 7.84% (2018–22) due to NNRTI. Pooled ADR prevalence (44.96%) increased, with NNRTI and NRTI aligning with the overall trend. The percentage of multidrug resistance was more than that of single-drug resistance in PDR and especially ADR annually. PDR was most prevalent in Central China followed by Southwest and North. ADR prevalence was highest in North China followed by Northwest and Southwest. In ADR sequences, high-level resistance was more common, especially in NRTI. PDR sequences exhibited low-level or intermediate resistance, especially PI. Drug resistance mutations revealed distinct patterns in PDR and ADR. CRF01_AE, the predominant subtype in China, exhibited the highest proportions among most ART drugs and drug resistance mutations, with a few exceptions where CRF07_BC (prominent in the Northwest), CRF55_01B and CRF08_BC (prominent in the Southwest) showed the highest proportions.
Conclusions
HIV-1 PDR and ADR prevalence in China exhibited diverse epidemiological characteristics, underscoring the importance of ongoing national monitoring of PDR, ADR and subtype; patient education on adherence; and personalized regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate School, Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
- Guangxi Key Laboratory of AIDS Prevention and Control and Achievement Transformation, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, China.
- Graduate School, Youjiang Medical University for Nationalities, Baise, Guangxi, China.
ORCID-Profile: Zhaoquan Wang, He Jiang, Jianjun Li, Guanghua Lan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Z., Jiang, H., Pang, X., Li, J., Liang, S., Huang, J., Li, D., Hou, W., Chen, N., & Lan, G. (2024). Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022. Journal of Antimicrobial Chemotherapy, 79(10), 2575-2585. https://doi.org/10.1093/jac/dkae260
Vancouver
Wang Z, Jiang H, Pang X, Li J, Liang S, Huang J, et al. Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022. Journal of Antimicrobial Chemotherapy. 2024;79(10):2575-2585. doi:10.1093/jac/dkae260
BibTeX
@article{Wang2024,
author = {Wang, Zhaoquan and Jiang, He and Pang, Xianwu and Li, Jianjun and Liang, Shujia and Huang, Jinghua and Li, Dejian and Hou, Wenxuan and Chen, Ni and Lan, Guanghua},
title = {Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 2022},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {10},
pages = {2575--2585},
doi = {10.1093/jac/dkae260}
}
EUVIMED